NEUROPHET, Inc. (KOSDAQ:380550)

South Korea · Delayed Price · Currency is KRW

6,870.00

+10.00 (0.15%)

Sep 18, 2026, 3:30 PM KST

NEUROPHET Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	2,590	2,615	2,216
Revenue Growth	-	18.00%	-
Gross Profit	2,584	2,611	2,215
Operating Income	-19,634	-16,549	-14,649
Net Income	-23,103	-22,389	-15,101
Earnings Per Share	-1969.42	-2301.74	-4091.00
EPS Growth	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	45,520	23,768	6,017
Total Debt	6,550	5,530	4,812
Net Cash (Debt)	38,970	18,238	1,206
Net Cash Growth	-	1412.64%	-
Net Cash Per Share	3321.94	1875.00	326.63

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-17,710	-15,067	-12,613
Capital Expenditures	-534	-265.46	-248.74
Free Cash Flow	-18,244	-15,332	-12,862
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	99.77%	99.85%	99.94%
Operating Margin	-758.18%	-632.84%	-660.98%
Pretax Margin	-912.11%	-856.15%	-681.41%
Profit Margin	-892.16%	-856.15%	-681.41%
FCF Margin	-704.52%	-586.30%	-580.35%

Valuation

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Sep '26 Sep 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
PS Ratio	32.36	99.01	-